These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

443 related items for PubMed ID: 7605351

  • 1. In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors lazabemide and N-(2-aminoethyl)-p-chlorobenzamide: a comparison with L-deprenyl.
    Bondiolotti GP, Galva MD, Villa F, Sciaba L, Picotti GB.
    Biochem Pharmacol; 1995 Jun 29; 50(1):97-102. PubMed ID: 7605351
    [Abstract] [Full Text] [Related]

  • 2. "In vitro" effect of some 5-hydroxy-indolalkylamine derivatives on monoamine uptake system.
    Morón JA, Perez V, Fernández-Alvarez E, Marco JL, Unzeta M.
    J Neural Transm Suppl; 1998 Jun 29; 52():343-9. PubMed ID: 9564637
    [Abstract] [Full Text] [Related]

  • 3. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
    Lamensdorf I, Youdim MB, Finberg JP.
    J Neurochem; 1996 Oct 29; 67(4):1532-9. PubMed ID: 8858937
    [Abstract] [Full Text] [Related]

  • 4. Effect of L-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake.
    Fang J, Yu PH.
    Neuropharmacology; 1994 Jun 29; 33(6):763-8. PubMed ID: 7936114
    [Abstract] [Full Text] [Related]

  • 5. (-)-Deprenyl inhibits tyramine-induced noradrenaline release, but not tyramine-induced dopamine release or potassium-induced noradrenaline release, from rat brain synaptosomes.
    Takahata K, Shimazu S, Yoneda F.
    Pharmacol Res; 2004 Mar 29; 49(3):253-8. PubMed ID: 14726221
    [Abstract] [Full Text] [Related]

  • 6. N-propargylbenzylamine, a major metabolite of pargyline, is a potent inhibitor of monoamine oxidase type B in rats in vivo: a comparison with deprenyl.
    Karoum F.
    Br J Pharmacol; 1987 Feb 29; 90(2):335-45. PubMed ID: 3103805
    [Abstract] [Full Text] [Related]

  • 7. A study of the biological pharmacology of IFO, a new selective and reversible monoamine oxidase-B inhibitor.
    Matsumoto J, Takahashi T, Agata M, Toyofuku H, Sasada N.
    Jpn J Pharmacol; 1994 May 29; 65(1):51-7. PubMed ID: 8089930
    [Abstract] [Full Text] [Related]

  • 8. Effect of MAO inhibitors on the high-affinity reuptake of biogenic amines in rat subcortical regions.
    Tekes K, Magyar K.
    Neurobiology (Bp); 2000 May 29; 8(3-4):257-64. PubMed ID: 11225517
    [Abstract] [Full Text] [Related]

  • 9. Combined treatment with MAO-A inhibitor and MAO-B inhibitor increases extracellular noradrenaline levels more than MAO-A inhibitor alone through increases in beta-phenylethylamine.
    Kitaichi Y, Inoue T, Nakagawa S, Boku S, Izumi T, Koyama T.
    Eur J Pharmacol; 2010 Jul 10; 637(1-3):77-82. PubMed ID: 20406628
    [Abstract] [Full Text] [Related]

  • 10. Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: preclinical and clinical findings.
    Henriot S, Kuhn C, Kettler R, Da Prada M.
    J Neural Transm Suppl; 1994 Jul 10; 41():321-5. PubMed ID: 7931245
    [Abstract] [Full Text] [Related]

  • 11. (-)-Trans-epsilon-viniferin, a polyphenol present in wines, is an inhibitor of noradrenaline and 5-hydroxytryptamine uptake and of monoamine oxidase activity.
    Yáñez M, Fraiz N, Cano E, Orallo F.
    Eur J Pharmacol; 2006 Aug 07; 542(1-3):54-60. PubMed ID: 16828740
    [Abstract] [Full Text] [Related]

  • 12. Inhibitory effects of cis- and trans-resveratrol on noradrenaline and 5-hydroxytryptamine uptake and on monoamine oxidase activity.
    Yáñez M, Fraiz N, Cano E, Orallo F.
    Biochem Biophys Res Commun; 2006 Jun 02; 344(2):688-95. PubMed ID: 16631124
    [Abstract] [Full Text] [Related]

  • 13. [3H]Ro 16-6491, a selective probe for affinity labelling of monoamine oxidase type B in human brain and platelet membranes.
    Cesura AM, Imhof R, Takacs B, Galva MD, Picotti GB, Da Prada M.
    J Neurochem; 1988 Apr 02; 50(4):1037-43. PubMed ID: 3126263
    [Abstract] [Full Text] [Related]

  • 14. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.
    Riederer P, Youdim MB.
    J Neurochem; 1986 May 02; 46(5):1359-65. PubMed ID: 2420928
    [Abstract] [Full Text] [Related]

  • 15. The activity of MAO A and B in rat renal cells and tubules.
    Guimarães JT, Soares-da-Silva P.
    Life Sci; 1998 May 02; 62(8):727-37. PubMed ID: 9489509
    [Abstract] [Full Text] [Related]

  • 16. Design, synthesis and biological evaluation of lazabemide derivatives as inhibitors of monoamine oxidase.
    Zhou S, Chen G, Huang G.
    Bioorg Med Chem; 2018 Sep 15; 26(17):4863-4870. PubMed ID: 30143367
    [Abstract] [Full Text] [Related]

  • 17. L-deprenyl inhibits tumor growth, reduces serum prolactin, and suppresses brain monoamine metabolism in rats with carcinogen-induced mammary tumors.
    ThyagaRajan S, Quadri SK.
    Endocrine; 1999 Jun 15; 10(3):225-32. PubMed ID: 10484286
    [Abstract] [Full Text] [Related]

  • 18. The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits.
    Sprague JE, Nichols DE.
    J Pharmacol Exp Ther; 1995 May 15; 273(2):667-73. PubMed ID: 7538579
    [Abstract] [Full Text] [Related]

  • 19. Antioxidant activity of the monoamine oxidase B inhibitor lazabemide.
    Mason RP, Olmstead EG, Jacob RF.
    Biochem Pharmacol; 2000 Sep 01; 60(5):709-16. PubMed ID: 10927030
    [Abstract] [Full Text] [Related]

  • 20. L-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors.
    Wachtel SR, Abercrombie ED.
    J Neurochem; 1994 Jul 01; 63(1):108-17. PubMed ID: 8207420
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.